Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study.
Antidiabetic agents
COVID-19
Diabetes mellitus
Long-term mortality
SARS-CoV-2
Journal
Journal of diabetes and metabolic disorders
ISSN: 2251-6581
Titre abrégé: J Diabetes Metab Disord
Pays: Switzerland
ID NLM: 101590741
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
12
07
2021
accepted:
13
09
2021
pubmed:
16
11
2021
medline:
16
11
2021
entrez:
15
11
2021
Statut:
epublish
Résumé
The prognostic factors of long-term outcomes in hospitalized patients with diabetes mellitus and COVID-19 are lacking. In this retrospective cohort study, we evaluated patients aged ≥ 18-years-old with the COVID-19 diagnosis who were hospitalized between Feb 20 and Oct 29, 2020, in the Sina Hospital, Tehran, Iran. 1323 patients with COVID-19 entered in the final analysis, of whom 393 (29.7%) patients had diabetes. We followed up patients for incurring in-hospital death, severe COVID-19, in-hospital complications, and 7-month all-cause mortality. By doing univariate analysis, variables with unadjusted P-value < 0.1 in univariate analyses were regarded as the confounders to include in the logistic regression models. We made adjustments for possible clinical (model 1) and both clinical and laboratory (model 2) confounders. After multivariable regression, it was revealed that preadmission use of sulfonylureas was associated with a borderline increased risk of severity in both models [model 1, OR (95% CI):1.83 (0.91-3.71), P-value: 0.092; model 2, 2.05 (0.87-4.79), P-value: 0.099] and major adverse events (MAE: each of the severe COVID-19, multi-organ damage, or in-hospital mortality) in model 1 [OR (95% CI): 1.86 (0.90-3.87), P-value: 0.094]. Preadmission use of ACEIs/ARBs was associated with borderline increased risk of MAE in the only model 1 [OR (95% CI):1.83 (0.96-3.48), P-value: 0.066]. Preadmission use of sulfonylureas and ACEIs/ARBs were associated with borderline increased risk of in-hospital adverse outcomes. The online version contains supplementary material available at 10.1007/s40200-021-00901-4.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic factors of long-term outcomes in hospitalized patients with diabetes mellitus and COVID-19 are lacking.
METHODS
METHODS
In this retrospective cohort study, we evaluated patients aged ≥ 18-years-old with the COVID-19 diagnosis who were hospitalized between Feb 20 and Oct 29, 2020, in the Sina Hospital, Tehran, Iran. 1323 patients with COVID-19 entered in the final analysis, of whom 393 (29.7%) patients had diabetes. We followed up patients for incurring in-hospital death, severe COVID-19, in-hospital complications, and 7-month all-cause mortality. By doing univariate analysis, variables with unadjusted P-value < 0.1 in univariate analyses were regarded as the confounders to include in the logistic regression models. We made adjustments for possible clinical (model 1) and both clinical and laboratory (model 2) confounders.
RESULTS
RESULTS
After multivariable regression, it was revealed that preadmission use of sulfonylureas was associated with a borderline increased risk of severity in both models [model 1, OR (95% CI):1.83 (0.91-3.71), P-value: 0.092; model 2, 2.05 (0.87-4.79), P-value: 0.099] and major adverse events (MAE: each of the severe COVID-19, multi-organ damage, or in-hospital mortality) in model 1 [OR (95% CI): 1.86 (0.90-3.87), P-value: 0.094]. Preadmission use of ACEIs/ARBs was associated with borderline increased risk of MAE in the only model 1 [OR (95% CI):1.83 (0.96-3.48), P-value: 0.066].
CONCLUSIONS
CONCLUSIONS
Preadmission use of sulfonylureas and ACEIs/ARBs were associated with borderline increased risk of in-hospital adverse outcomes.
SUPPLEMENTARY INFORMATION
BACKGROUND
The online version contains supplementary material available at 10.1007/s40200-021-00901-4.
Identifiants
pubmed: 34778117
doi: 10.1007/s40200-021-00901-4
pii: 901
pmc: PMC8573568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1545-1555Informations de copyright
© Springer Nature Switzerland AG 2021.
Déclaration de conflit d'intérêts
Conflict of interestAll authors declare that they have no competing interests.
Références
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
Arch Acad Emerg Med. 2020 Mar 14;8(1):e24
pubmed: 32259119
Microcirculation. 2007 Jun-Jul;14(4-5):363-73
pubmed: 17613808
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Int Urol Nephrol. 2020 Jun;52(6):1193-1194
pubmed: 32222883
Diabetes Care. 2020 Oct;43(10):2339-2344
pubmed: 32769128
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2177-2183
pubmed: 33395778
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2
pubmed: 32674818
Diabetes Metab J. 2021 Mar;45(2):251-259
pubmed: 33752274
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309
pubmed: 32231171
Am J Cardiol. 2020 Nov 1;134:153-155
pubmed: 32891399
Diabetologia. 2021 Apr;64(4):778-794
pubmed: 33599800
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Cell Discov. 2020 Oct 29;6(1):77
pubmed: 33298897
Lancet Healthy Longev. 2021 Jan;2(1):e34-e41
pubmed: 33521772
BMC Med. 2020 Nov 16;18(1):359
pubmed: 33190637
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Diabetes Care. 2020 Dec;43(12):2999-3006
pubmed: 32994187
Curr Hypertens Rep. 2020 Sep 10;22(11):90
pubmed: 32910274
Clin Chem. 2000 Dec;46(12):2050-68
pubmed: 11106350
Clin Transl Sci. 2020 Nov;13(6):1055-1059
pubmed: 32955785
Diabetes Metab J. 2020 Aug;44(4):602-613
pubmed: 32794386
Curr Diab Rep. 2019 Jul 29;19(9):65
pubmed: 31353426
PLoS Med. 2016 Apr 12;13(4):e1001992
pubmed: 27071029
Front Endocrinol (Lausanne). 2021 Jan 13;11:600439
pubmed: 33519709
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):415-416
pubmed: 32501477
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Pharmacol Res. 2020 Sep;159:105033
pubmed: 32562814
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Diabetes Res Clin Pract. 2020 Jun;164:108229
pubmed: 32446798
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320979097
pubmed: 33283602
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716
pubmed: 32220930
Am J Hypertens. 2020 Dec 31;33(12):1102-1111
pubmed: 32920644
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
BMJ Open Diabetes Res Care. 2021 Jan;9(1):
pubmed: 33408084
Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e48-e51
pubmed: 32766831
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613-1615
pubmed: 32882643
Intern Emerg Med. 2020 Nov;15(8):1415-1424
pubmed: 32772283
Diabetes Care. 2017 May;40(5):706-714
pubmed: 28428321
Viruses. 2020 Apr 28;12(5):
pubmed: 32354022
J Investig Med. 2020 Oct;68(7):1261-1270
pubmed: 32655013
J Diabetes Metab Disord. 2021 Jan 07;20(1):59-69
pubmed: 33432296
Eur Heart J. 2010 Sep;31(18):2197-204
pubmed: 20685679
J Diabetes Metab Disord. 2021 Mar 31;20(1):939-950
pubmed: 33821206